Pharming Group N V 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Pharming Group N V in the fourth quarter 2025?
Pharming Group N v achieved a return on average equity (ROE) of 0.92 % in its fourth quarter 2025, which is below Pharming Group N V 's average return on equity, which stands at 1.14%.

ROE has advanced compared to -4.5% in the third quarter 2025, due to net income growth.

Within the Major Pharmaceutical Preparations industry 71 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the third quarter 2025 from 0 to 2351.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Dec 31 2025) IV. Quarter	0 III. Quarter	0 II. Quarter	0 I. Quarter	(Dec 31 2024) IV. Quarter
Y / Y Equity Change	25.35 %	25.35 %	25.35 %	25.35 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	3	-12	-12	-12	-12
Return On Equity (TTM)	0.92 %	-4.5 %	-4.75 %	-5.04 %	-5.36 %
PHAR's Total Ranking	# 2351	# 0	#	#	#
Equity (TTM) in Millions	277	277	277	277	221
Seq. Equity Change	0 %	0 %	0 %	25.35 %	0 %
Seq. Net Income Change	-	-	-	-	-

Back to PHAR Management Effectiveness >> PHAR's 5 Years Annual ROE >> Compare PHAR ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 72
Sector	# 211
Overall	# 2351

Return On Equity Statistics
High	Average	Low
8.29 %	1.14 %	-5.36 %
(Dec 31 2021)		(Dec 31 2024)

PHAR Annual Return On Equity	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Equity in Millions	277	221	219	205	193
Y / Y Equity Change	25.35 %	1.04 %	6.91 %	6.08 %	5.17 %
Net Income in Millions	3	-12	-11	14	16
Y / Y Net Income Change	-	-	-	-14.52 %	-57.62 %
Return On Equity	0.92 %	-5.36 %	-4.82 %	6.68 %	8.29 %

Back to PHAR Management Effectiveness >> PHAR's 5 Years Annual ROE >> Compare PHAR ROE to its Competitors

Annual Roe Comment

In 2025 ROE improved to 0.92 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
PHAR's' Return on Equity at Yahoo Finance
PHAR's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for PHAR's Competitors
Subscribers only: Roe for Pharming Group N V 's Suppliers
Subscribers only: Return On Equity for PHAR's Customers

Companies with similar Return On Equity at Dec 31 2025, within Healthcare Sector	ROE
Icon Plc	2.49 %
Artivion Inc	2.44 %
Repligen Corp	2.37 %
Envista Holdings Corporation	1.52 %
Innovage Holding Corp	1.37 %
Radnet Inc	1.37 %
Castle Biosciences Inc	1.17 %
Pacira Biosciences inc	0.95 %
Pharming Group N v	0.92 %
Lifestance Health Group Inc	0.65 %
Warby Parker Inc	0.45 %
Perspective Therapeutics Inc	0.32 %

Date modified: 2026-07-07T12:47:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.